PMID- 23667712
OWN - NLM
STAT- MEDLINE
DCOM- 20131217
LR  - 20231115
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Effects of resveratrol in pregnancy using murine models with reduced blood supply 
      to the uterus.
PG  - e64401
LID - 10.1371/journal.pone.0064401 [doi]
LID - e64401
AB  - Preeclampsia (PE) and fetal growth restriction (FGR) contribute significantly to 
      fetal and maternal morbidity and mortality. Although the causes of PE and FGR are 
      not fully understood, both conditions are known to be associated with impaired 
      uterine artery blood flow. Resveratrol, a polyphenol found in a number of plants, 
      has been shown to induce relaxation of uterine arteries in vitro as well as 
      improve many pathological conditions associated with PE and FGR. We hypothesized 
      that treatment of endothelial nitric oxide synthase knockout mice (eNOS(-)/(-)) and 
      catechol-O-methyltransferase knockout mice (COMT(-)/(-)) with resveratrol during 
      pregnancy would improve uterine artery blood flow and therefore ameliorate the 
      PE-like phenotype and FGR in these murine models. Pregnant C57BL/6J, eNOS(-)/(-) and 
      COMT(-)/(-) mice received either resveratrol supplemented diet (4 g/kg diet) or 
      control diet between gestational day (GD) 0.5 and GD 18.5. Resveratrol 
      supplementation significantly increased uterine artery blood flow velocity and 
      fetal weight in COMT(-)/(-) but not in eNOS(-)/(-) mice. There were no effects of 
      resveratrol on litter size and placental weight among the groups. In conclusion, 
      resveratrol increased uterine artery blood flow velocity and fetal weight in 
      COMT(-)/(-) mice, suggesting potential as a therapeutic strategy for PE and FGR.
FAU - Poudel, Rajan
AU  - Poudel R
AD  - University of Alberta, Edmonton, Alberta, Canada.
FAU - Stanley, Joanna L
AU  - Stanley JL
FAU - Rueda-Clausen, Christian F
AU  - Rueda-Clausen CF
FAU - Andersson, Irene J
AU  - Andersson IJ
FAU - Sibley, Colin P
AU  - Sibley CP
FAU - Davidge, Sandra T
AU  - Davidge ST
FAU - Baker, Philip N
AU  - Baker PN
LA  - eng
GR  - G0802770/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130508
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Stilbenes)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 2.1.1.6 (Catechol O-Methyltransferase)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Blood Flow Velocity/drug effects
MH  - Blood Pressure/drug effects/physiology
MH  - Catechol O-Methyltransferase/genetics
MH  - Female
MH  - Fetal Growth Retardation/*drug therapy
MH  - Fetal Weight/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Microscopy, Acoustic
MH  - Nitric Oxide Synthase Type III/genetics
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Proteinuria
MH  - Regional Blood Flow/drug effects/*physiology
MH  - Resveratrol
MH  - Stilbenes/*pharmacology/therapeutic use
MH  - Uterus/*blood supply
PMC - PMC3648569
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/05/15 06:00
MHDA- 2013/12/18 06:00
PMCR- 2013/05/08
CRDT- 2013/05/14 06:00
PHST- 2013/03/02 00:00 [received]
PHST- 2013/04/15 00:00 [accepted]
PHST- 2013/05/14 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
PHST- 2013/05/08 00:00 [pmc-release]
AID - PONE-D-13-08973 [pii]
AID - 10.1371/journal.pone.0064401 [doi]
PST - epublish
SO  - PLoS One. 2013 May 8;8(5):e64401. doi: 10.1371/journal.pone.0064401. Print 2013.